Antibody drug conjugates (ADCs) are emerging therapeutic agents that chemically combine a monoclonal antibody to a cytotoxic drug, most often used to treat cancer in a more targeted way than traditional chemotherapy. Here, Tom Held shares why the advancement of ADCs is exciting for the pharma industry, highlighting the benefits of this new therapeutic approach, the key challenges in manufacturing, and his hopes for the future of the space.